Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Equity Average (2017 - 2025)

Historic Equity Average for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $110.0 million.

  • Puma Biotechnology's Equity Average rose 8393.94% to $110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.0 million, marking a year-over-year increase of 8393.94%. This contributed to the annual value of $72.8 million for FY2024, which is 9396.0% up from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Equity Average is $110.0 million, which was up 8393.94% from $100.9 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Equity Average ranged from a high of $110.0 million in Q3 2025 and a low of -$6.7 million during Q4 2021
  • For the 5-year period, Puma Biotechnology's Equity Average averaged around $40.6 million, with its median value being $28.1 million (2023).
  • Per our database at Business Quant, Puma Biotechnology's Equity Average plummeted by 10874.45% in 2021 and then skyrocketed by 90989.57% in 2023.
  • Over the past 5 years, Puma Biotechnology's Equity Average (Quarter) stood at -$6.7 million in 2021, then surged by 427.37% to $21.9 million in 2022, then soared by 110.64% to $46.1 million in 2023, then surged by 77.05% to $81.6 million in 2024, then soared by 34.78% to $110.0 million in 2025.
  • Its Equity Average was $110.0 million in Q3 2025, compared to $100.9 million in Q2 2025 and $94.6 million in Q1 2025.